The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Jun. 02, 2015
Applicant:

Phio Pharmaceuticals Corp., Marlborough, MA (US);

Inventors:

Tod M. Woolf, Sudbury, MA (US);

Joanne Kamens, Newton, MA (US);

Anastasia Khvorova, Westborough, MA (US);

William Salomon, Worcester, MA (US);

Assignee:

Phio Pharmaceuticals Corp., Marlborough, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); C12Y 207/01037 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2320/11 (2013.01); C12N 2320/30 (2013.01);
Abstract

RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2'-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing.


Find Patent Forward Citations

Loading…